A new weight-loss medication, eloralintide, has demonstrated significant weight reduction in trials, with some participants losing up to 20% of their body weight. The drug, developed by Eli Lilly, is a weekly injection that targets the amylin receptor and may offer benefits beyond current GLP-1 medications. However, experts caution that while the results are promising, more research is needed before it becomes widely available.